Koers Sangui Biotech International, Inc. Other OTC
Aandelen
SGBI
US80105B1017
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 65,58K 61,34K | Omzet 2022 | 69,19K 64,71K | Marktkapitalisatie | 3,09 mln. 2,89 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | - 0 | Nettowinst (verlies) 2022 | - 0 | EV/omzet 2021 | 90,6 x |
Nettoschuld 2021 | 790K 739K | Nettoschuld 2022 | 795K 743K | EV/omzet 2022 | 56,1 x |
K/w-verhouding 2021 |
-25,6
x | K/w-verhouding 2022 |
-51,8
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 86,94% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 07-02-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Striepe
CEO | Chief Executive Officer | 62 | 07-02-05 |
Hubertus Schmelz
BRD | Director/Board Member | 68 | 18-12-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |